Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,548.00
Ask: 12,550.00
Change: 6.00 (0.05%)
Spread: 2.00 (0.016%)
Open: 12,570.00
High: 12,704.00
Low: 12,472.00
Prev. Close: 12,550.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: UK Stocks Fall As US GDP Surge Turns Attention To Fed

Wed, 30th Jul 2014 16:34

LONDON (Alliance News) - UK stocks had a choppy trading session Wednesday and ultimately closed lower, while the dollar gained against other major currencies, as some heavily anticipated US GDP data showed the world's biggest economy more than reversed its first quarter slump.

The surprisingly strong US economy shifted the market focus squarely onto the Federal Reserve policy announcement still to come Wednesday.

The US economy grew at an annualised rate of 4.0% in the second quarter, more than reversing the 2.1% contraction in the first quarter, which was also revised up from the original 2.9% drop.

The data has been a long time coming for a market hoping for a sharp reversal in US economic growth following the first-quarter contraction, which was broadly blamed on particularly harsh winter weather. However, despite the reading causing an initial surge in global equity markets to session highs, investors have since reverted to caution ahead of a potential change of tone from the Federal Open Market Committee announcement at 1900 BST.

Concern over the potential economic impact of new sanctions from the EU and the US against Russia also have continued to weigh on general sentiment, and particularly the energy sector.

The FTSE 100 closed down 0.5% at 6,773.44 and the FTSE 250 down 0.4% at 15,629.84, while the AIM All-Share outperformed, closing up 0.1% at 772.25.

Within major European markets, the German DAX 30 ended down 0.6% and the French CAC 40 down 1.2%

After the European close, US markets continue to trade mixed, with the DJIA down 0.4%, the S&P 500 down 0.2%, and the Nasdaq Composite up 0.2%.

"The (US) data lends more credence to arguments that the Federal Reserve is nearing its mandates and this may bring forward speculation of when the Fed delivers its first rate hike," said Brown Brothers Harriman's Global Head of Currency Strategy Marc Chandler.

The dollar was the best performing currency in the wake of the bumper US GDP reading. The pound fell to the lowest level in six weeks, bottoming at USD1.6885, while the euro fell to its lowest level in more than eight months, bottoming at USD1.3364.

The UK banking sector provided the main downside support to the FTSE 100 after Barclays followed in Royal Bank of Scotland's recent footsteps by releasing first-half results ahead of analyst expectations.

Barclays said it made a GBP3.35 billion adjusted pretax profit in the first six months of 2014, down from a GBP3.59 billion profit in the year before but ahead of the GBP2.96 billion consensus forecast. Barclays also updated as to its progress on capital ratios, with the CET1 ratio increasing to 9.9% and the PRA leverage ratio increasing to 3.4% in the first half.

"The shares have been terrible performers of late so the profit beat and good progress on capital should come as a welcome relief to the market," said Shore Capital analyst Gary Greenwood.

Barclays ended as the top FTSE 100 gainer, up 4.5%, while RBS closed up 2.8%, and Lloyds, which reports its own results on Thursday, closed up 1.0%.

The bank shares envinced little concern over new Bank of England proposals, unveiled Wednesday, to increase individual responsibility and accountability in the banking sector, with changes including a new approval regime for the most senior bankers and new rules on bonuses.

Travis Perkins gained 2.7% after reporting a rise in pretax profit to GBP153.7 million in the first half, up 14% from the previous year, with the company citing improving market conditions and increased customer confidence. The group's consumer division, which incorporates DIY chain Wickes, saw revenue rise 8.8%.

Pets at Home was the top FTSE 250 gainer, closing up 7.1% after saying like-for-like sales were up 4.1% in the second quarter, boosted by a return to TV advertising and its VIP loyalty scheme. Despite the positive update, which boosted the Pets at Home to 182 pence Wednesday, the stock remains well below its March IPO price of 245p.

Mining stocks weighed on the other end of the market, led lower by Antofagasta, which closed down 4.6% at the bottom of the FTSE 100 after reporting production rates in line with expectations, but also a 16% rise in its net cash costs. Antofagasta has generally underperformed the other copper miners so far this year, which analysts attribute to its significant cost inflation.

Although the new sanctions from the EU and the US on Russia over its hand in the crisis in Ukraine are still short on details, the knowledge that they are on the way kept the energy sector in the red, with Royal Dutch Shell, BG Group, and BP down 1.8%, 1.8%, and 0.5%, respectively.

Given Fed Chair Janet Yellen's insistence that future monetary policy is not on a pre-set course and instead is data-dependent, it would not be unreasonable to expect a shift in the tone of the statement given the bumper US GDP reading just released.

While the statement, which follows the FOMC's two-day meeting, will be closely watched for such a change, it is highly unlikely that the central bank will deviate from the path of tapering asset purchases, and another USD10 billion cut is widely expected, which would leave the Fed on course to finish its quantitative easing programme in October.

Given Yellen's recent comment that US social media stocks are looking stretched, she and her colleagues at the FOMC will no doubt have watched with interest as Twitter jumped another 25% at the opening bell Wednesday, after announcing a huge extension of its user base, which grew by 16 million in the second quarter, adding huge future advertising potential.

Looking towards Thursday, while any unexpected commentary from the Federal Reserve has the potential to provide an early driver for markets, European data will be in focus, with unemployment numbers from across the region due throughout the morning and July eurozone CPI released at 1000 BST.

Another busy day in the UK corporate calendar Thursday brings interim results from Lloyds Banking Group, as well as its recently spun-off retail arm TSB Group. While it's the first update from TSB since its late June flotation, the expectations for Lloyds has been raised by the strong results reported Wednesday and last Friday by peers Barclays and Royal Bank of Scotland.

Drinks giant Diageo is scheduled released full-year results Thursday, while other names with interim results slated include BG Group, Centrica, AstraZeneca, BAE Systems, Rolls-Royce, Weir Group, Countrywide, and Intu Properties.

By Jon Darby; jondarby@alliancenews.com; @jondarby100

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
3 Nov 2023 11:34

AstraZeneca's Lokelma lets kidney disease patients maintain therapy

(Alliance News) - AstraZeneca PLC on Thursday celebrated results from an observational study, which showed that treating hyperkalaemia with the potassium binder, Lokelma, allows chronic kidney disease and heart failure patients to maintain RAASi therapy.

Read more
2 Nov 2023 15:57

UK earnings, trading statements calendar - next 7 days

Friday 3 November 
no events scheduled 
Monday 6 November 
Kingspan Group PLCTrading Statement
Kosmos Energy LtdQ3 Results
Ryanair Holdings PLCHalf Year Results
Tuesday 7 November 
Associated British Foods PLCFull Year Results
Beazley PLCQ3 Results
Direct Line Insurance Group PLCTrading Statement
dotdigital Group PLCFull Year Results
IWG PLCQ3 Results
Persimmon PLCTrading Statement
RS Group PLCHalf Year Results
Vaalco Energy IncQ3 Results
Watches of Switzerland Group PLCTrading Statement
Wednesday 8 November 
Conduit Holdings LtdQ3 Results
ITV PLCTrading Statement
JD Wetherspoon PLCQ1 Results
Marks & Spencer Group PLCHalf Year Results
MaxCyte IncQ3 Results
Secure Trust Bank PLCTrading Statement
Smiths News PLCFull Year Results
Time Out Group PLCFull Year Results
Thursday 9 November 
3i Group PLCHalf Year Results
Apax Global Alpha LtdQ3 Results
AstraZeneca PLCQ3 Results
Auto Trader Group PLCHalf Year Results
B&M European Value Retail SAHalf Year Results
Domino's Pizza Group PLCTrading Statement
Endeavour Mining PLCQ3 Results
Flutter Entertainment PLCTrading Statement
IMI PLCTrading Statement
Indivior PLCQ3 Results
John Wood Group PLCTrading Statement
Lancashire Holdings LtdTrading Statement
National Grid PLCHalf Year Results
Regional REIT LtdTrading Statement
Renewi PLCHalf Year Results
S4 Capital PLCTrading Statement
Tate & Lyle PLCHalf Year Results
Taylor Wimpey PLCTrading Statement
TBC Bank Group PLCQ3 Results
TheWorks.co.uk PLCTrading Statement
Trakm8 Holdings PLCHalf Year Results
Urban Logistics REIT PLCHalf Year Results
Vistry Group PLCTrading Statement
WH Smith PLCFull Year Results
Wincanton PLCHalf Year Results
Wizz Air Holdings PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
1 Nov 2023 08:59

AstraZeneca launches collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Wednesday announced a new collaboration and investment agreement with clinical-stage biotechnology company Cellectis.

Read more
1 Nov 2023 07:33

AstraZeneca invests $220m in French gene-editing group Cellectis

(Sharecast News) - AstraZeneca is to invest in French biopharma group Cellectis to use its gene-editing technologies to develop next-gen therapeutics in areas like oncology, immunology and rare diseases.

Read more
30 Oct 2023 09:40

LONDON BROKER RATINGS: Jefferies cuts NatWest to underperform from buy

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
25 Oct 2023 11:04

PRESS: Soriot commits to five more years as AstraZeneca CEO - Times

(Alliance News) - Pascal Soriot has committed to remaining as chief executive officer of AstraZeneca PLC for another five years, The Times reported on Wednesday.

Read more
24 Oct 2023 17:08

LONDON MARKET CLOSE: FTSE 100 shakes off midday losses after US data

(Alliance News) - The FTSE 100 closed in the green on Tuesday following positive private sector data out of the US, despite figures closer to home showing a weaker UK private sector and rising unemployment.

Read more
24 Oct 2023 11:06

AstraZeneca says US accepts self-administered flu vaccine for review

(Alliance News) - AstraZeneca PLC on Tuesday said the US health watchdog has approved a review for its FluMist Quadrivalent self-administered flu vaccine, for which the drugmaker is seeking a green light.

Read more
23 Oct 2023 17:50

AstraZeneca celebrates drug trial results for cancer indications

(Alliance News) - AstraZeneca PLC on Monday said new drugs, developed in partnership with Daiichi Sankyo Co Ltd, showed positive results in patients with solid tumours, lung and breast cancer.

Read more
23 Oct 2023 17:08

LONDON MARKET CLOSE: Stocks largely down on Middle East hostilities

(Alliance News) - Stock prices in London closed largely lower on Monday, as investors were unable to shake off concerns surrounding the conflict in the Middle East, while developments in the US bond market added to the drama.

Read more
23 Oct 2023 08:45

TOP NEWS: AstraZeneca says Enhertu approved by European Commission

(Alliance News) - AstraZeneca PLC on Monday said its Enhertu treatment has been approved by the European Commission to treat adult lung cancer patients.

Read more
23 Oct 2023 07:46

LONDON BRIEFING: Keller expects higher profit; Upland rejects approach

(Alliance News) - Stocks in London are set to open slightly higher on Monday, as risk sentiment improves after a difficult period for markets last week.

Read more
18 Oct 2023 09:04

AstraZeneca drug Solaris approved in China as NMOSD treatment

(Alliance News) - AstraZeneca PLC on Wednesday announced that eculizumab, whose brand name is Solaris, has been approved in China to treat patients with neuromyelitis optica spectrum disorder

Read more
17 Oct 2023 12:06

LONDON MARKET MIDDAY: European markets uneasy but FTSE 100 outperforms

(Alliance News) - London's FTSE 100 higher was higher around midday, though it was defensive stocks such as utilities and pharmaceuticals which led the charge, suggesting there is still lingering discomfort in markets amid tensions in the Middle East.

Read more
16 Oct 2023 08:34

TOP NEWS: AstraZeneca's cancer drug gets priority review from US FDA

(Alliance News) - AstraZeneca PLC on Monday said that its new drug application for Tagrisso has been granted priority review in the US, after trial results extended progression-free survival.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.